About Advaxis
Advaxis is a Healthcare company based in Princeton (United States) founded in 2002, and was acquired by BioSight in July 2021. Cancer immunotherapies are developed using a proprietary Listeria-based platform. The company has 12 employees. Advaxis has completed 1 acquisition, including BioSight. The company was acqui-hired. Advaxis offers products and services including Togel Platform and Full Bet System. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Advaxis was founded in 2002 in Princeton, United States, and operates in the biotechnology sector focused on oncology. Immunotherapies are developed through a proprietary platform that employs bioengineered live attenuated Listeria monocytogenes to target the tumor microenvironment. The immune system is redirected to suppress tumor growth, with efforts centered on cancer treatment applications. Operations emphasize research and development of these bacterial vector technologies for therapeutic use.
- Headquarters Princeton, United States
- Employees 12
- Stage Public
- SectorsHealthcare
- Website advaxis.com
- Social LinkedIn X Facebook
- Acquired by BioSight (Jul 2021)
- InvestorsT. Rowe Price
& 7 more
- Employee Count12
- Investments & Acquisitions
- Acquired byBioSight
(Jul 2021)
Products & Services of Advaxis
Advaxis offers a comprehensive portfolio of products and services, including Togel Platform and Full Bet System.
Service for playing togel lottery games with high payout options
System allowing full bet placements on lottery numbers for maximum rewards
Funding Insights of Advaxis
- Total Rounds 18
- First Round $210,739
(Aug 2009)
- Investors Count 7
Latest 10 of 18 funding rounds of Advaxis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | Post-IPO | – | – | – | |
| Aug 2020 | Post-IPO | – | – | ||
| Jan 2020 | $10.5M | Post-IPO | – | – | – |
| Aug 2015 | $25M | Post-IPO | – | – | |
| May 2015 | $53.2M | Post-IPO | – | – | – |
| Feb 2015 | $23M | Post-IPO | – | – | |
| Jun 2012 | $715,000 | Post-IPO | – | – | – |
| May 2012 | $4.47M | Post-IPO | – | – | – |
| Feb 2012 | $1.05M | Post-IPO | – | – | – |
| Nov 2011 | $1.98M | Post-IPO | – | – | – |
8 investors in total: 8 institutional.
Investors in Advaxis
Advaxis has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include T. Rowe Price, HHS and Knight Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States | ||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Investment opportunities in healthcare are managed by Broadfin Capital. | 2005 | broadfin.com | Melville, United States | |
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company. | 2014 | gud-knight.com | Westmount, Canada | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Therapeutics for oncology and hematological disorders are developed. | 2000 | biosight-pharma.com | Karmiel, Israel |
Investor details for Advaxis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Advaxis
14 people are tracked at Advaxis (9 in leadership, 5 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Kenneth A. Berlin | President & CEO | Leadership |
Sherrie Balog | Administrative Manager/Sr. Executive Assistant to the CEO | Leadership |
Maurice Lobo | Associate Director | Leadership |
Aaron Smith | Associate Director of Facilities/Warehouse and Materials Manager | Leadership |
Elaine Gosden | Supply Chain Director | Leadership |
Igor Gitelman | Interim Chief Financial Officer | Leadership |
Michael Grace | Executive Director | Leadership |
jiaxin zhang | Chief Medical Officer | Leadership |
Frances Gavigan | Associate Director, Clinical Quality Assurance | Leadership |
David Estrella | Senior Manager, Quality (QA/QC) | Team |
David Ruiz | Manager, IT & Facilities | Team |
Colline Staton | Senior HR Manager | Team |
Latisha Williams | Desktop Support Lead | Team |
Emeka Chiedu | Engineering Manager | Team |
Complete people profiles for Advaxis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Advaxis
Advaxis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BioSight.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for oncology and hematological disorders are developed. | biosight-pharma.com | Karmiel, Israel | 2000 | Jul 2021 | •••• |
Complete acquisition details for Advaxis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Advaxis
6 dated milestones of Advaxis across 19 years, from founding to its latest funding, stage changes and deals.
Competitors of Advaxis
Advaxis has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Advaxis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Advaxis
Websites that share an audience with Advaxis (advaxis.com).
Websites whose visitors overlap most with Advaxis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| kancera.com | 100% | #4,801,729 | View details | ||
| clevelandheartlab.com | 64% | 23.1K | #1,301,267 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Advaxis (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Advaxis
Complete news archive for Advaxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Advaxis
Advaxis was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Advaxis is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Advaxis has 12 employees.
Advaxis was founded in 2002 in Princeton, United States, and operates in the biotechnology sector focused on oncology. Immunotherapies are developed through a proprietary platform that employs bioengineered live attenuated Listeria monocytogenes to target the tumor microenvironment. The immune system is redirected to suppress tumor growth, with efforts centered on cancer treatment applications. Operations emphasize research and development of these bacterial vector technologies for therapeutic use.
Advaxis offers Togel Platform and Full Bet System.
Advaxis has made 1 acquisition, including BioSight.
Advaxis has 8 investors. Key investors include T. Rowe Price, HHS, Knight Therapeutics, BioSight, and Lincoln Park Capital.
Yes. Advaxis was acquired by BioSight in July 2021.